Studies Support the Use of Suvorexant for the Prevention of Delirium

Muneto Izuhara, MD, MSc; Hisae Kihara Izuhara, MD; Keiko Tsuchie, MSc; Tomoko Araki, MSc; Tsukasa Ito, MD; Kouhei Sato, MD; Syoko Miura, MD; Koji Otsuki, MD, PhD; Michiharu Nagahama, MD; Maiko Hayashida, MD, PhD; Sadayuki Hashioka, MD, PhD; Rei Wake, MD, PhD; Tomohiro Kimura, BSc; Shusaku Tsumoto, MD, PhD; Yoji Saito, MD, PhD; Masatoshi Inagaki, MD, PhD

J Clin Psychiatry 2021;82(3):20lr13818a

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

References (10)

Brooks III JO, Kruse JL. It is too early to put delirium prophylaxis to bed : stronger evidence is needed for suvorexant. J Clin Psychiatry. 2021;82(3):20lr13818.
Izuhara M, Izuhara HK, Tsuchie K, et al. Real-world preventive effects of suvorexant in intensive care delirium: a retrospective cohort study. J Clin Psychiatry. 2020;81(6):20m13362. PubMed CrossRef
Hatta K, Kishi Y, Wada K, et al; DELIRIA-J Group. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. J Clin Psychiatry. 2017;78(8):e970–e979. PubMed CrossRef
Azuma K, Takaesu Y, Soeda H, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg. 2018;5(4):362–368. PubMed CrossRef
Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–120. PubMed CrossRef
Tamura K, Maruyama T, Sakurai S. Preventive effect of suvorexant for postoperative delirium after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2019;25(1):26–31. PubMed CrossRef
Masuyama T, Sanui M, Yoshida N, et al. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics. 2018;18(3):209–215. PubMed CrossRef
Hatta K, Kishi Y, Wada K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. J Clin Psychiatry. 2019;81(1):19m12865. PubMed CrossRef
Booka E, Tsubosa Y, Matsumoto T, et al. Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant. Esophagus. 2017;14(3):229–234. PubMed CrossRef
Kawada K, Ohta T, Tanaka K, et al. Addition of suvorexant to ramelteon therapy for improved sleep quality with reduced delirium risk in acute stroke patients. J Stroke Cerebrovasc Dis. 2019;28(1):142–148. PubMed CrossRef